Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 40
- Registration Number
- NCT06429098
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, Jiangsu, China
🇨🇳Ethical Committee of the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Conditions
- T-cell LymphomaT-cell Acute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06390319
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2025-03-05
- Target Recruit Count
- 53
- Registration Number
- NCT06387121
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
- Conditions
- Classic Hodgkin LymphomaAutologous Stem Cell Transplant
- Interventions
- Procedure: Autologous stem cell transplant
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 28
- Registration Number
- NCT06377540
- Locations
- 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
- Conditions
- Relapsed/Refractory KMT2A-r Acute LeukemiaRelapsed/Refractory NUP98-r Acute LeukemiaRelapsed/Refractory NPM1-m Acute Leukemia
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- LLS PedAL Initiative, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT06376162
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL
- Conditions
- ETP-ALL
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 81
- Registration Number
- NCT06361329
- Locations
- 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Ma-Spore ALL 2020 Study
- Conditions
- B Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 500
- Registration Number
- NCT06336395
- Locations
- 🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Subang Jaya Medical Centre, Kuala Lumpur, Malaysia
🇸🇬KK Women's and Children's Hospital, Singapore, Singapore
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
- Conditions
- Relapse/RecurrenceC-KIT MutationCore Binding Factor Acute Myeloid LeukemiaAML, ChildhoodRefractory AML
- Interventions
- Drug: Granulocyte Colony-Stimulating Factor
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Children's Hospital of Soochow University
- Target Recruit Count
- 50
- Registration Number
- NCT06316960
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳Kaifeng Children's Hospital, Kaifeng, Henan, China
🇨🇳Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Conditions
- B Acute Lymphoblastic LeukemiaAcute Leukemia of Ambiguous Lineage
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: FDG-Positron Emission TomographyProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition Scan
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 153
- Registration Number
- NCT06317662
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Albany Medical Center, Albany, New York, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
Revumenib in Combination With 7+3 + Midostaurin in AML
- Conditions
- AML With Gene MutationsAMLLeukemiaAML, AdultAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Richard Stone, MD
- Target Recruit Count
- 22
- Registration Number
- NCT06313437
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.